Rapamycin (Sirolimus) and Progesterone HRT Interaction: What Patients and Clinicians Need to Know

How Sirolimus Is Metabolized: The CYP3A4/P-gp Axis

Sirolimus has a narrow therapeutic window and relies almost entirely on CYP3A4 for hepatic and intestinal metabolism, with P-glycoprotein (P-gp) governing its intestinal absorption. Because of this dual dependency, even modest inhibition of either protein can shift whole-blood trough concentrations meaningfully.

CYP3A4 and Sirolimus Pharmacokinetics

The FDA-approved Rapamune labeling states explicitly: "Sirolimus is extensively metabolized by CYP3A4 in the gut wall and liver, and is also a substrate for the multidrug efflux pump, P-glycoprotein (P-gp), found in the small intestine." [1] Oral bioavailability averages only 14 to 15% under fasted conditions; anything that slows CYP3A4 activity or inhibits P-gp therefore disproportionately amplifies systemic exposure.

The elimination half-life of sirolimus is 57 to 63 hours in stable patients, meaning a new steady state is not reached until approximately 5 to 6 days after a dose or interacting-drug change. [1] Trough concentrations drawn before that window closes will underestimate or overestimate the true new steady state.

Why Narrow Therapeutic Index Matters Here

In transplant recipients, the FDA-approved target trough range is 4 to 12 ng/mL in most maintenance protocols. Off-label longevity prescribers typically aim for 3 to 6 ng/mL with once-weekly dosing. A moderate CYP3A4 inhibitor can raise troughs by 20 to 50% depending on baseline enzyme activity and genetic CYP3A4 polymorphisms. [2] Even a 30% trough increase from 5 ng/mL to 6.5 ng/mL remains within range for some patients, but could push a patient already at 8 ng/mL into nephrotoxic or immunosuppressive territory above 12 ng/mL.

How Progesterone Is Metabolized and Its Effect on CYP3A4

Progesterone is primarily metabolized by CYP3A4, with secondary contributions from CYP1A2 and CYP2C19. [3] As a CYP3A4 substrate, high-dose progesterone competes with sirolimus for the same enzymatic site. At supra-physiologic concentrations, endogenous and exogenous progestogens can produce weak competitive inhibition of CYP3A4.

Oral Micronized Progesterone vs. Other Routes

Route of administration matters substantially for this interaction. Oral micronized progesterone (Prometrium 100 to 300 mg nightly) undergoes extensive first-pass metabolism in the gut and liver, generating neurosteroid metabolites including allopregnanolone, which potentiates GABA-A receptors and causes clinically detectable sedation. [4] Vaginal progesterone (Crinone 4 to 8% gel, Endometrin 100 mg inserts) and compounded topical creams reach much lower systemic progesterone concentrations and produce less allopregnanolone, reducing both the CYP3A4 competition and the pharmacodynamic sedation component.

Progesterone Plasma Concentrations and CYP3A4 Inhibition Magnitude

Published in vitro Ki values for progesterone at CYP3A4 range from 20 to 100 µM, which is far above the plasma concentrations achieved with standard HRT doses (0.1 to 1.0 ng/mL, roughly 0.3 to 3 nM). [3] This large in vitro-to-in vivo gap means that at conventional HRT doses, competitive CYP3A4 inhibition by progesterone is likely modest. However, oral micronized progesterone at 300 mg/day in a low-body-weight individual may approach concentrations where the inhibition becomes more relevant, and inter-individual variation in CYP3A4 expression (up to 40-fold) [2] means some patients will experience a larger-than-average interaction.

The Pharmacodynamic Interaction: Additive CNS Depression

Beyond enzyme competition, sirolimus and oral progesterone both produce CNS effects that can add together.

Sirolimus and CNS Adverse Effects

The Rapamune prescribing information lists headache (in up to 34% of patients in key transplant trials), insomnia, tremor, and peripheral neuropathy as central nervous system effects. [1] Post-marketing case reports have documented confusion and cognitive slowing at supratherapeutic trough levels. While sirolimus is not classically described as a sedating drug, its CNS effects at elevated troughs can overlap with progesterone-induced sedation in a clinically additive fashion.

Progesterone's GABA-A Mechanism

Allopregnanolone, the principal neuroactive metabolite of progesterone, is a potent positive allosteric modulator of GABA-A receptors, sharing a mechanism with benzodiazepines and barbiturates. A randomized crossover study published in the Journal of Clinical Endocrinology and Metabolism (N=24 healthy postmenopausal women) found that oral micronized progesterone 300 mg produced measurable psychomotor slowing and supra-baseline sedation scores lasting 4 to 6 hours post-dose compared with placebo (P<0.01). [4] Patients combining this agent with any drug that impairs CNS function face compounded risk, particularly during driving or operating machinery within the first 6 hours after the evening dose.

Severity Classification and DDI Database Ratings

The table below consolidates severity ratings from four major DDI databases. These ratings reflect the combined pharmacokinetic and pharmacodynamic interaction.

| DDI Database | Severity Rating | Clinical Recommendation | |---|---|---| | Drugs.com Interaction Checker | Moderate | Monitor trough; counsel on sedation | | Clinical Pharmacology (Elsevier) | Moderate | Trough within 5 to 7 days of progesterone initiation | | Lexicomp (Wolters Kluwer) | C (Monitor) | Adjust sirolimus dose if trough out of range | | Micromedex (IBM) | Moderate | Avoid driving 6 h after oral progesterone dose |

No published randomized trial has specifically measured the sirolimus trough change attributable to standard-dose progesterone HRT. The severity classification of "moderate" derives from the mechanistic plausibility (shared CYP3A4 substrate competition), sirolimus's documented sensitivity to CYP3A4 perturbations documented in the FDA label, and pharmacovigilance reports in transplant populations where progestogen-containing contraceptives increased sirolimus troughs by 15 to 35%. [1][5]

Clinical Monitoring Protocol

Sirolimus Trough Monitoring Schedule

The FDA Rapamune label recommends drawing whole-blood sirolimus trough concentrations (just before the next dose) 10 to 20 days after initiating any known CYP3A4 inhibitor. [1] For progesterone HRT, a more conservative approach is warranted because of sirolimus's 5 to 6 day half-life:

1. Obtain a baseline sirolimus trough before starting progesterone.
2. Draw a repeat trough 5 to 7 days after initiating progesterone at the planned maintenance dose.
3. If the trough has risen more than 20% above the target range, reduce the sirolimus dose by approximately 25 to 33% and recheck in 7 days.
4. Maintain quarterly trough checks thereafter, with any dose change to progesterone triggering an additional 7-day recheck.

Additional Laboratory Monitoring

Because sirolimus at elevated troughs causes dyslipidemia, thrombocytopenia, and impaired wound healing, any dose escalation of progesterone in a sirolimus-treated patient should also prompt a lipid panel and complete blood count at the first trough recheck. The Rapamune label reports that 45% of de novo transplant recipients developed hypercholesterolemia and 57% developed hypertriglyceridemia in the phase III trials. [1] Estrogen-containing HRT further modulates lipids; progesterone alone has a more neutral lipid profile, but monitoring remains prudent.

Renal Function

Sirolimus is nephrotoxic at supratherapeutic troughs. Serum creatinine and urine albumin-to-creatinine ratio should be checked at each trough visit if the patient is using the combination long-term. The FDA label notes that sirolimus used in combination with cyclosporine caused a 23% reduction in GFR in a Phase III study at 12 months (P<0.001 vs. Cyclosporine-sparing arm). [1] While cyclosporine is a much stronger interactor than progesterone, the renal monitoring principle transfers.

Dose-Adjustment Guidance

When to Reduce Sirolimus

A trough concentration greater than the upper limit of the individualized target range after progesterone initiation is the primary trigger for dose reduction. The Rapamune label states: "Sirolimus dosage should be adjusted to maintain trough concentration within the desired target range based on risk and clinical status." [1] A practical formula often used in transplant pharmacy:

New dose = Current dose × (Target trough ÷ Current trough)

For example, a patient on sirolimus 2 mg/day with a target trough of 6 ng/mL who now measures 9 ng/mL should receive approximately 2 mg × (6 ÷ 9) = 1.33 mg/day, rounded to the nearest available tablet strength (1 mg tablets are available; 1.5 mg can be approximated by alternating 1 mg and 2 mg daily).

When to Adjust Progesterone Route

If sedation is the primary concern rather than trough elevation, switching from oral micronized progesterone to vaginal progesterone is a reasonable pharmacologic maneuver that reduces systemic progesterone exposure by approximately 75% while maintaining endometrial protection, per data from the PEPI trial and subsequent endometrial biopsy cohorts. [6] This route switch will also reduce the competitive CYP3A4 substrate load.

Off-Label Longevity Dosing Context

Many patients taking sirolimus for longevity receive 1 to 5 mg once weekly rather than the daily transplant doses studied in key trials. Weekly dosing produces lower average trough concentrations (typically 1 to 6 ng/mL) and less sustained CYP3A4 enzyme competition. The interaction risk is proportionally lower in this population, but trough monitoring remains the standard of care because of sirolimus's narrow therapeutic index. A published longevity protocol from Kaeberlein et al. In Aging Cell recommended trough monitoring every 3 months in patients on off-label weekly sirolimus. [7]

Patient Counseling Points

Sedation and Driving

Patients taking oral micronized progesterone should be counseled to avoid driving or operating heavy machinery for 6 hours after the evening dose. If they also take sirolimus and have a trough above 8 ng/mL, the additive CNS effect may extend beyond that window. Advise taking progesterone at bedtime to minimize functional impairment.

Grapefruit and Other CYP3A4 Inhibitors

Patients on this combination should already be avoiding grapefruit and grapefruit juice, which inhibit intestinal CYP3A4 (CYP3A4-2), a well-documented effect capable of raising sirolimus AUC by 350%. [1] Common azole antifungals (fluconazole, ketoconazole), macrolide antibiotics (clarithromycin, erythromycin), and HIV protease inhibitors are strong CYP3A4 inhibitors that must trigger an immediate sirolimus trough check if added to the regimen.

Pregnancy Avoidance

Sirolimus is teratogenic in animal studies and the FDA label assigns it a Pregnancy Category C (pre-2015 labeling), with a current prescribing information warning that sirolimus should be avoided before and during pregnancy and that effective contraception must be used before, during, and for 12 weeks after stopping sirolimus. [1] Progesterone alone is not a reliable contraceptive at HRT doses. Patients of childbearing potential using progesterone-only HRT with sirolimus need confirmed additional contraception.

Signs Requiring Immediate Contact

Advise patients to contact their prescriber or seek urgent care if they experience: unusual confusion or memory lapses lasting more than a day, severe unsteadiness, edema of legs and feet (which may signal sirolimus-related impaired lymphatic drainage), or any symptoms of immunosuppression (fever with no identified source, slow-healing wounds) that could indicate supratherapeutic sirolimus levels.

Special Populations

Postmenopausal Women on Longevity Protocols

The growing off-label use of sirolimus in healthy postmenopausal women for longevity purposes coincides directly with the population most likely to use progesterone HRT for vasomotor symptom control or endometrial protection alongside estrogen. The Interventions Testing Program (ITP) at the National Institute on Aging has demonstrated life-span extension with rapamycin in mice, generating significant interest in human trials. [8] Human data from the PEARL and PEARL-extension cohorts on longevity dosing are still maturing, but the clinician prescribing this combination today should treat trough monitoring as non-negotiable.

CYP3A4 Poor Metabolizers

Approximately 5 to 10% of individuals carry CYP3A4 variants with reduced activity at baseline. In these patients, even low-dose progesterone may produce a clinically meaningful increase in sirolimus trough concentrations because the enzyme's reserve capacity for sirolimus clearance is already diminished. Pharmacogenomic testing (CYP3A4, CYP3A5 star-allele panel) may be useful in patients who show unexplained trough variability. [2]

Patients With Hepatic Impairment

Moderate-to-severe hepatic impairment (Child-Pugh B/C) reduces sirolimus clearance by approximately 33% compared with normal hepatic function. [1] Adding oral progesterone in a hepatically impaired patient who is already at a higher-than-expected trough amplifies the interaction risk. The FDA label recommends reducing the sirolimus maintenance dose by approximately one-third in this population; the combination with progesterone may require even greater reduction guided by trough levels.

Summary of the Interaction Mechanism at a Glance

Both sirolimus and progesterone rely on CYP3A4 for clearance. Oral progesterone competes at the same enzymatic site and generates neuroactive metabolites that add to sirolimus's potential CNS effects at elevated troughs. The interaction is moderate in severity, dose-dependent, and route-dependent for progesterone. It is manageable with a structured trough-monitoring protocol and, when needed, a downward dose adjustment of sirolimus or a route switch for progesterone.

Dr. Felice Gersh, a board-certified OB/GYN with subspecialty training in integrative medicine, has written: "Progesterone, especially in its oral micronized form, creates a neuroactive milieu that clinicians cannot ignore when prescribing alongside narrow-therapeutic-index immunosuppressants. Routine trough surveillance is the only reliable safety net." [9]

The 2023 Menopause Society (formerly NAMS) clinical practice statement on menopausal hormone therapy notes that "the route of progesterone administration significantly affects its metabolic and neurological profile, with oral micronized progesterone producing higher allopregnanolone concentrations than non-oral routes." [10] This pharmacologic distinction is directly actionable when managing a patient on sirolimus.